CN1176690C - Medicine for treating chronic nephritis - Google Patents
Medicine for treating chronic nephritis Download PDFInfo
- Publication number
- CN1176690C CN1176690C CNB021133395A CN02113339A CN1176690C CN 1176690 C CN1176690 C CN 1176690C CN B021133395 A CNB021133395 A CN B021133395A CN 02113339 A CN02113339 A CN 02113339A CN 1176690 C CN1176690 C CN 1176690C
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- chronic nephritis
- poria
- treatment chronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a medicine which is prepared from astragalus root, epimedium herb, pilose asiabell root, cassia twig, eucommia bark, Indian bread, prepared rehmannia root, red peony root, motherwort herb and cooked rhubarb. The medicine has conspicuous therapeutical effect on chronic nephritis.
Description
The present invention relates to a kind of medicine for the treatment of chronic nephritis.Be the Chinese medicine of feedstock production specifically, the invention still further relates to the preparation method of this medicine with the Chinese herbal medicine.
Chronic nephritis is one of worldwide difficult treatment, develops into uremia the most at last and crisis life.(Dai Jingzhang etc. the chronic nephritis card is controlled discussion. the journal .1995 of Beijing University of Chinese Medicine, 18 (6) .53-54) numerous for many years medical science scholar and expert, though this treatment of diseases method has been done number of research projects, still there are many drawbacks in up to the present existing therapeutic method of traditional Chinese and western medicine.As, when doctor trained in Western medicine is treated with 17-hydroxy-11-dehydrocorticosterone, can be concurrent burst itch, hemorrhage, hypertension or adverse consequences such as azotemia occurs, and when treating with phosphamide, adverse consequencess such as leukocyte can appear then reducing, and also unstable with the curative effect of western medical treatment, recur easily; For another example, the traditional Chinese medical science generally adopts the decoction treatment by Chinese herbs, and this not only can make patient's sup sorrow in taking the decoction process for a long time, and therapeutic effect is also undesirable.(China Patent No. 98113708.3)
The objective of the invention is to be to provide a kind of therapeutic effect better, toxic and side effects is little, the Chinese medicine of the treatment chronic nephritis of taking convenience.The present invention also aims to provide a kind of preparation method of medicine of the present invention.
Solution of the present invention is based on understanding and the Therapeutic Principle of motherland's medical science to chronic nephritis mechanism, kidney master water, The spleen has the function to transport and transform nutrients, and water is wet, and with the passing of time nephropathy must cause deficiency of spleen-YANG and kidneyYANG, yang deficiency can not warm blood vessels, pathogen usually intruding into collateral in protracted disease in addition, all causing blood stasis is trouble, so the chronic nephritis deficiency of spleen-YANG and kidneyYANG has the blood stasis accompanied symptoms more, form prescription of the present invention with the medicine of the kidney warming spleen reinforcing, blood circulation promoting and blood stasis dispelling, be used for the treatment of the chronic nephritis deficiency of spleen-YANG and kidneyYANG syndrome of blood stasis of holding concurrently.
Medicine of the present invention is made by following components in weight percentage:
Radix Astragali 10-25% Herba Epimedii 6-16% Radix Codonopsis 6-16%
Ramulus Cinnamomi 4-12% Cortex Eucommiae 5-15% Poria 5-15%
Radix Rehmanniae Preparata 5-15% Radix Paeoniae Rubra 6-16% Herba Leonuri 6-16%
Radix Et Rhizoma Rhei 1-4%
The formula optimization weight percentage ranges of preparation medicine of the present invention is:
Radix Astragali 10-20% Herba Epimedii 9-15% Radix Codonopsis 9-15%
Ramulus Cinnamomi 4-10% Cortex Eucommiae 7-12% Poria 7-12%
Radix Rehmanniae Preparata 7-12% Radix Paeoniae Rubra 9-15% Herba Leonuri 9-15%
Radix Et Rhizoma Rhei 2-4%
The optimum weight percentage ratio of medicine of the present invention is:
The Radix Astragali 14% Herba Epimedii 12% Radix Codonopsis 12%
Ramulus Cinnamomi 7% Cortex Eucommiae 9.5% Poria 9.5%
Radix Rehmanniae Preparata 9.5% Radix Paeoniae Rubra 12% Herba Leonuri 12%
Radix Et Rhizoma Rhei 2.5%
The said Radix Astragali of the present invention, Herba Epimedii, Radix Codonopsis, Ramulus Cinnamomi, the Cortex Eucommiae, Poria, Radix Rehmanniae Preparata, Radix Paeoniae Rubra, Herba Leonuri, Radix Et Rhizoma Rhei all use and meet " Chinese crude drug or the decoction pieces of 2000 editions one ministerial standards of Chinese pharmacopoeia.
Adopt the routine techniques in present medical industry field, the component of above-mentioned prescription can be prepared into the pharmaceutical dosage form that the various patients of being suitable for use.
Because of capsule can improve stability of drug, production technology is simple among the present invention, is convenient to mechanization production, is advantages such as clinical common formulations, so select capsule.
Said components is made medicine production method of the present invention is:
1, get prescription and partly measure Poria, 80 ℃ of dryings are pulverized, and cross 80 mesh sieves, and the fine powder radiosterilization is standby.
2, all the other medical materials person twice that adds the decocting adds 8-12 times of water gaging for the first time, adds 6-9 times of water gaging for the second time, decocts l-2 hour at every turn.Collecting decoction filters, and filtrate is concentrated into the extractum of relative density about 1.10 (70 ℃), and spray drying gets dry extract.
3, get dry extract, add the Poria fine powder, mixing incapsulates, promptly.
Medicine of the present invention has following advantage:
L, Drug therapy chronic nephritis of the present invention are effective.
2, the present invention is a capsule, taking convenience.
3, poisonous side effect of medicine of the present invention is little.
Although the preferred capsule of pharmaceutical dosage form of the present invention,, as long as adopted the composition of raw materials of medicine of the present invention, but make the pharmaceutical formulation that any other patients uses, all within protection scope of the present invention.
Medicine QI invigorating warming YANG of the present invention, blood circulation promoting and blood stasis dispelling.Be used for chronic nephritis deficiency of spleen-YANG and kidneyYANG hold concurrently edema, complexion due to the syndrome of blood stasis
White or dark and gloomy, aversion to cold and cold limbs, ache of the spinal column or twinge do not move or the soreness of the shank lower limb soft, Mental fatigue, indigestion and loss of appetite or loose stool, the not normal or menoxenia of sexual function, diseases such as squamous and dry skin or numb limbs and tense tendons.
In order to confirm the medical function of medicine of the present invention, following a series of experiment and clinical observation have been carried out.
One, acute toxicity test
Measure normal mouse and irritated the maximum tolerated dose of stomach medicine of the present invention in, and observed its toxic reaction.The result is as follows:
The maximum tolerated dose that twice is irritated stomach medicine of the present invention in the mice one day is 326 times of clinical application amount at 134.4g crude drug/kg.
Two, long term toxicity test
Medicine of the present invention is given rat continuous irrigation stomach 6 months with every day 42g/kg and 21g/kg (quite clinical 50kg people's one consumption per day 100 times with 50 times), to routine blood test, liver, renal function and main organs coefficient (heart, liver, spleen, lung, kidney, adrenal gland, thymus, testis, ovary, uterus) all do not have obviously influence, and body weight gain and behavioral activity are normal.Pathologic finding shows, respectively organizes the rat heart, liver, spleen, lung, kidney, adrenal gland, thymus, stomach, testis, ovary, the 11 kinds of main organs in uterus under the light microscopic and do not have obvious histopathology damage.The slowness toxic reaction does not appear in 4 weeks of drug withdrawal.Show medicine of the present invention to the safe dose of rat long term administration more than 42g/kg.
Three, rat AHN nephritis there is therapeutical effect preferably
Method with injection allogenic animal renal cortex+Freund's complete adjuvant has successfully been duplicated rat AHN nephritis model, its 24h urine protein significantly raises, Hb and serum ALB reduce, and T-CHO increases, and histopathologic examination shows that its pathological change is very similar to people's membraneous nephritis (disease).
With medicine of the present invention this model continuous irrigation stomach was treated for 5 weeks, high and low dose group 24h urine protein all obviously reduces than treatment is preceding, and significantly is lower than the model group same period, and Hb and serum ALB all have rise, and T-CHO descends, with acting as significantly of high dose.Serum BUN, Crea and body weight gain there is not obvious influence.Pathologic finding demonstration treatment group glomerular capillary GBM thickens obviously and alleviates, electron-dense thing deposition reduces, part is that cell, endotheliocyte pathological changes are improved, podocytic process merges and alleviates, reduces, more obvious with high dose group, its bead blood capillary GBM, podocyte and endotheliocyte majority are tending towards normal.
Four, QI invigorating warming YANG effect
Give the medicine of the present invention of height, middle dosage, can the significant prolongation normal mouse and swimming time and time-to-live at low temperatures and the survival rate of yang deficiency mice, show that this medicine has resisting fatigue and cold-resistant function.
Five, diuresis
Medicine of the present invention can increase the voided volume of water load rat, 1～3h after the high dose group administration, and the voided volume of 1～2h is significantly more than matched group after the low dose group administration.
Embodiment
The Radix Astragali 14% Herba Epimedii 12% Radix Codonopsis 12%
Ramulus Cinnamomi 7% Cortex Eucommiae 9.5% Poria 9.5%
Radix Rehmanniae Preparata 9.5% Radix Paeoniae Rubra 12% Herba Leonuri 12%
Radix Et Rhizoma Rhei 2.5%
Production method is as follows:
1, get prescription and partly measure Poria, 80 ℃ of dryings are pulverized, and cross 80 mesh sieves, and the fine powder radiosterilization is standby.
2, all the other medical materials person twice that adds the decocting adds 10 times of water gagings for the first time, adds 8 times of water gagings for the second time, decocts 1.5 hours at every turn.Collecting decoction filters, and filtrate is concentrated into the extractum of relative density about 1.10 (70 ℃), and spray drying gets dry extract.
3, get dry extract, add the Poria fine powder, mixing incapsulates, promptly.
Claims (6)
1, a kind of medicine for the treatment of chronic nephritis is characterized in that it is to be made by following weight percentages:
Radix Astragali 10-25% Herba Epimedii 6-16% Radix Codonopsis 6-16%
Ramulus Cinnamomi 4-12% Cortex Eucommiae 5-15% Poria 5-15%
Radix Rehmanniae Preparata 5-15% Radix Paeoniae Rubra 6-16% Herba Leonuri 6-16%
Radix Et Rhizoma Rhei 1-4%.
2, the medicine of treatment chronic nephritis according to claim 1, wherein the percentage by weight of each raw material is:
Radix Astragali 10-20% Herba Epimedii 9-15% Radix Codonopsis 9-15%
Ramulus Cinnamomi 4-10% Cortex Eucommiae 7-12% Poria 7-12%
Radix Rehmanniae Preparata 7-12% Radix Paeoniae Rubra 9-15% Herba Leonuri 9-15%
Radix Et Rhizoma Rhei 2-4%.
3, the medicine of treatment chronic nephritis according to claim 1, wherein the percentage by weight of each raw material is:
The Radix Astragali 14% Herba Epimedii 12% Radix Codonopsis 12%
Ramulus Cinnamomi 7% Cortex Eucommiae 9.5% Poria 9.5%
Radix Rehmanniae Preparata 9.5% Radix Paeoniae Rubra 12% Herba Leonuri 12%
Radix Et Rhizoma Rhei 2.5%.
4, according to the medicine of claim 1,2 or 3 described treatment chronic nephritiss, the dosage form that it is characterized in that this medicine is a capsule.
5, the preparation method of the medicine of treatment chronic nephritis according to claim 4 is characterized in that: get half amount Poria, 80 ℃ of dryings are pulverized, and cross 80 mesh sieves, and the fine powder radiosterilization is standby; All the other medical materials add decocting person twice adds 8-12 times of water gaging for the first time, adds 6-9 times of water gaging for the second time, decocts 1-2 hour at every turn; Collecting decoction filters, and it is 1.10 extractum that filtrate is concentrated into 70 ℃ of relative densities, and spray drying gets dry extract; Dry extract adds the Poria fine powder, and mixing incapsulates, promptly.
6, the preparation method of the medicine of treatment chronic nephritis according to claim 5, wherein amount of water is 10 times for the first time, amount of water is 8 times for the second time, decocts 1.5 hours at every turn.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021133395A CN1176690C (en) | 2002-02-07 | 2002-02-07 | Medicine for treating chronic nephritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021133395A CN1176690C (en) | 2002-02-07 | 2002-02-07 | Medicine for treating chronic nephritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1369303A CN1369303A (en) | 2002-09-18 |
| CN1176690C true CN1176690C (en) | 2004-11-24 |
Family
ID=4742570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021133395A Expired - Fee Related CN1176690C (en) | 2002-02-07 | 2002-02-07 | Medicine for treating chronic nephritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1176690C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100353960C (en) * | 2003-12-25 | 2007-12-12 | 王苓芝 | Yinhuang enema liquid for kindney deficiency and its preparing method |
| CN100364585C (en) * | 2005-09-21 | 2008-01-30 | 上海玉森新药开发有限公司 | Medicine for treating chronic kidney function deficiency and preparation method |
| CN1839928B (en) * | 2006-01-16 | 2010-11-17 | 重庆医药工业研究院有限责任公司 | Chinese traditional medicine for treating chronic nephritis and its preparation process |
| CN104998040A (en) * | 2015-08-03 | 2015-10-28 | 李强 | Medicine treating chronic glomerulonephritis |
-
2002
- 2002-02-07 CN CNB021133395A patent/CN1176690C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1369303A (en) | 2002-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103272169B (en) | Application of rhodiola rosea compound composite in treating erosive gastritis | |
| CN1312098A (en) | A medicated liquor for treating arthralgia syndrome such as rheumatism and rheumatoid diseases | |
| CN1742939A (en) | Medicine for treating pulmonary fibrosis and preparing method | |
| CN102058817A (en) | Tibetan medicinal preparation for treating liver diseases | |
| CN103386022B (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN1286502C (en) | Medicine for treating gout affection and its symptoms | |
| CN101584758A (en) | A kind of pharmaceutical composition for the treatment of kidney deficiency | |
| CN1259955C (en) | Chinese medicine preparation for treating climacteric metancholia of women | |
| CN1176690C (en) | Medicine for treating chronic nephritis | |
| CN102416126A (en) | Chinese medicinal combination preparation for treating behcet syndrome and preparation method of Chinese medicinal combination preparation | |
| CN103356932B (en) | A kind of pharmaceutical composition for the treatment of vulva squamous epithelial hyperplasia | |
| CN1899586A (en) | Chinese medicine preparation for treating gynecologic inflammation and its preparing method | |
| CN1772119A (en) | Medicine for treating coronary heart disease and angina pectoris and its prepn | |
| CN1879783A (en) | A medicine for treating diabetes | |
| CN100342888C (en) | Chinese medicine preparation for treating prostatic hyperplasia | |
| CN1294980C (en) | Medicine for treating liver disease | |
| CN1107711A (en) | Hypoglycemic compound capsule | |
| CN101066425A (en) | Chinese medicine prepn for treating ungual mycosis | |
| CN1272054C (en) | Medicine for treating diabetes and its preparing process | |
| CN1850247A (en) | Pure Chinese medicine for treating hyperplasia of mammary glands and preparing method | |
| CN104645144A (en) | Traditional Chinese medicine preparation for treating nephritis and preparation method of traditional Chinese medicine preparation | |
| CN1092968C (en) | Pharmaceuticals for treating outer skin blood vessel diease in cold seasons | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN100341563C (en) | Chinese medicinal capsule for treating metrorrhagia and metrostaxis | |
| CN1709298A (en) | Chinese medicine formulation for treating chronic prostatitis and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CI01 | Correction of invention patent gazette |
Correction item: Patentee Correct: Kanghong Science & Tech. Industrial (Group) Co., Ltd., Chengdu False: Kanghong Pharmaceutical Co., Ltd., Chengdu Number: 47 Page: 496 Volume: 20 |
|
| CI03 | Correction of invention patent |
Correction item: Patentee Correct: Kanghong Science & Tech. Industrial (Group) Co., Ltd., Chengdu False: Kanghong Pharmaceutical Co., Ltd., Chengdu Number: 47 Page: The title page Volume: 20 |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: PATENTEE; FROM: CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. TO: CHENGDU KANGHONG TECHNOLOGY INDUSTRIAL (GROUP) CO., LTD. |
|
| ERR | Gazette correction |
Free format text: CORRECT: PATENTEE; FROM: CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. TO: CHENGDU KANGHONG TECHNOLOGY INDUSTRIAL (GROUP) CO., LTD. |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Da Xiaoling Document name: patent for invention |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |